727 related articles for article (PubMed ID: 30761132)
1. Repurposing of Drugs as Novel Influenza Inhibitors From Clinical Gene Expression Infection Signatures.
Pizzorno A; Terrier O; Nicolas de Lamballerie C; Julien T; Padey B; Traversier A; Roche M; Hamelin ME; Rhéaume C; Croze S; Escuret V; Poissy J; Lina B; Legras-Lachuer C; Textoris J; Boivin G; Rosa-Calatrava M
Front Immunol; 2019; 10():60. PubMed ID: 30761132
[TBL] [Abstract][Full Text] [Related]
2. Drug Repurposing Approaches for the Treatment of Influenza Viral Infection: Reviving Old Drugs to Fight Against a Long-Lived Enemy.
Pizzorno A; Padey B; Terrier O; Rosa-Calatrava M
Front Immunol; 2019; 10():531. PubMed ID: 30941148
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of influenza virus replication by plant-derived isoquercetin.
Kim Y; Narayanan S; Chang KO
Antiviral Res; 2010 Nov; 88(2):227-35. PubMed ID: 20826184
[TBL] [Abstract][Full Text] [Related]
4. Discovery of a Novel Specific Inhibitor Targeting Influenza A Virus Nucleoprotein with Pleiotropic Inhibitory Effects on Various Steps of the Viral Life Cycle.
Yang F; Pang B; Lai KK; Cheung NN; Dai J; Zhang W; Zhang J; Chan KH; Chen H; Sze KH; Zhang H; Hao Q; Yang D; Yuen KY; Kao RY
J Virol; 2021 Apr; 95(9):. PubMed ID: 33627391
[TBL] [Abstract][Full Text] [Related]
5. Host-targeted nitazoxanide has a high barrier to resistance but does not reduce the emergence or proliferation of oseltamivir-resistant influenza viruses in vitro or in vivo when used in combination with oseltamivir.
Tilmanis D; Koszalka P; Barr IG; Rossignol JF; Mifsud E; Hurt AC
Antiviral Res; 2020 Aug; 180():104851. PubMed ID: 32544408
[TBL] [Abstract][Full Text] [Related]
6. Targeting organic anion transporter 3 with probenecid as a novel anti-influenza a virus strategy.
Perwitasari O; Yan X; Johnson S; White C; Brooks P; Tompkins SM; Tripp RA
Antimicrob Agents Chemother; 2013 Jan; 57(1):475-83. PubMed ID: 23129053
[TBL] [Abstract][Full Text] [Related]
7. Combinatory Treatment with Oseltamivir and Itraconazole Targeting Both Virus and Host Factors in Influenza A Virus Infection.
Schloer S; Goretzko J; Pleschka S; Ludwig S; Rescher U
Viruses; 2020 Jun; 12(7):. PubMed ID: 32610711
[TBL] [Abstract][Full Text] [Related]
8. Repurposing Kinase Inhibitors as Antiviral Agents to Control Influenza A Virus Replication.
Perwitasari O; Yan X; O'Donnell J; Johnson S; Tripp RA
Assay Drug Dev Technol; 2015 Dec; 13(10):638-49. PubMed ID: 26192013
[TBL] [Abstract][Full Text] [Related]
9.
Lloren KKS; Kwon JJ; Choi WS; Jeong JH; Ahn SJ; Choi YK; Baek YH; Song MS
J Virol; 2019 Mar; 93(6):. PubMed ID: 30602610
[TBL] [Abstract][Full Text] [Related]
10. Cell type- and replication stage-specific influenza virus responses in vivo.
Fay EJ; Aron SL; Macchietto MG; Markman MW; Esser-Nobis K; Gale M; Shen S; Langlois RA
PLoS Pathog; 2020 Aug; 16(8):e1008760. PubMed ID: 32790753
[TBL] [Abstract][Full Text] [Related]
11. FDA-Approved Inhibitors of RTK/Raf Signaling Potently Impair Multiple Steps of In Vitro and Ex Vivo Influenza A Virus Infections.
Meineke R; Stelz S; Busch M; Werlein C; Kühnel M; Jonigk D; Rimmelzwaan GF; Elbahesh H
Viruses; 2022 Sep; 14(9):. PubMed ID: 36146864
[TBL] [Abstract][Full Text] [Related]
12. Verdinexor, a novel selective inhibitor of nuclear export, reduces influenza a virus replication in vitro and in vivo.
Perwitasari O; Johnson S; Yan X; Howerth E; Shacham S; Landesman Y; Baloglu E; McCauley D; Tamir S; Tompkins SM; Tripp RA
J Virol; 2014 Sep; 88(17):10228-43. PubMed ID: 24965445
[TBL] [Abstract][Full Text] [Related]
13. Targeting the host or the virus: current and novel concepts for antiviral approaches against influenza virus infection.
Lee SM; Yen HL
Antiviral Res; 2012 Dec; 96(3):391-404. PubMed ID: 23022351
[TBL] [Abstract][Full Text] [Related]
14. Screening and identification of inhibitors against influenza A virus from a US drug collection of 1280 drugs.
An L; Liu R; Tang W; Wu JG; Chen X
Antiviral Res; 2014 Sep; 109():54-63. PubMed ID: 24971493
[TBL] [Abstract][Full Text] [Related]
15. In vitro evaluation of synergistic inhibitory effects of neuraminidase inhibitors and methylglyoxal against influenza virus infection.
Charyasriwong S; Watanabe K; Rahmasari R; Matsunaga A; Haruyama T; Kobayashi N
Arch Med Res; 2015 Jan; 46(1):8-16. PubMed ID: 25523147
[TBL] [Abstract][Full Text] [Related]
16. Anti-Influenza Drug Discovery and Development: Targeting the Virus and Its Host by All Possible Means.
Terrier O; Slama-Schwok A
Adv Exp Med Biol; 2021; 1322():195-218. PubMed ID: 34258742
[TBL] [Abstract][Full Text] [Related]
17. Transcriptomic characterization of the novel avian-origin influenza A (H7N9) virus: specific host response and responses intermediate between avian (H5N1 and H7N7) and human (H3N2) viruses and implications for treatment options.
Josset L; Zeng H; Kelly SM; Tumpey TM; Katze MG
mBio; 2014 Feb; 5(1):e01102-13. PubMed ID: 24496798
[TBL] [Abstract][Full Text] [Related]
18. Baloxavir marboxil, a novel cap-dependent endonuclease inhibitor potently suppresses influenza virus replication and represents therapeutic effects in both immunocompetent and immunocompromised mouse models.
Fukao K; Ando Y; Noshi T; Kitano M; Noda T; Kawai M; Yoshida R; Sato A; Shishido T; Naito A
PLoS One; 2019; 14(5):e0217307. PubMed ID: 31107922
[TBL] [Abstract][Full Text] [Related]
19. Discovery of Influenza A Virus Sequence Pairs and Their Combinations for Simultaneous Heterosubtypic Targeting that Hedge against Antiviral Resistance.
Wee KB; Lee RT; Lin J; Pramono ZA; Maurer-Stroh S
PLoS Comput Biol; 2016 Jan; 12(1):e1004663. PubMed ID: 26771381
[TBL] [Abstract][Full Text] [Related]
20. Drugs in development for influenza.
Boltz DA; Aldridge JR; Webster RG; Govorkova EA
Drugs; 2010 Jul; 70(11):1349-62. PubMed ID: 20614944
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
